Quantcast
Last updated on April 18, 2014 at 17:08 EDT

Latest Monoclonal antibodies Stories

2014-02-19 08:31:28

Proceeds Bring Series B to CHF 44.9 Million ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million. The additional financing will primarily...

2014-02-17 23:02:51

Biosimilars Products Market report is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html) (PRWEB) February 17, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) -...

2014-02-12 16:22:08

DUBLIN, February 12, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/d8gv2t/chromatography) has announced the addition of the "Concise Analysis of the International Chromatography Resin Market - Trends & Forecast to 2018" [http://www.researchandmarkets.com/research/d8gv2t/chromatography ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Ever increasing application in monoclonal...

2014-02-07 12:39:53

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of new antibacterial therapies. The protein's unique ability to...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-02-06 16:27:50

MONROVIA, Calif., Feb. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 2:15 p.m. EST at the Waldorf Astoria Hotel in New York, NY. A live audio...

2014-02-05 20:26:52

SOUTH SAN FRANCISCO, Calif., Feb. 5, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: -- 16(th) Annual BIO CEO & Investor ConferenceTuesday, February 11, 2014 in New York City8:30 AM Eastern Time (5:30 AM Pacific Time) -- Leerink Global Healthcare Conference 2014Thursday, February 13, 2014 in New...

2014-02-03 08:27:04

INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. (Logo:...

2014-01-31 23:24:50

The Biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (PRWEB) January 31, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major...

2014-01-31 23:24:23

OriGene Technologies, Inc. (“OriGene”), one of the industry leaders in producing genome wide products for research and diagnostic applications, has been awarded a contract from the National Cancer Institute (NCI) to develop high affinity anti-peptide antibodies for SISCAPA assays. Rockville, MD (PRWEB) January 31, 2014 Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), an approach developed by Dr. Leigh Anderson, is a novel technology that can achieve high...